{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:53:35Z","timestamp":1740124415930,"version":"3.37.3"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T00:00:00Z","timestamp":1430870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"crossref","award":["2009-0094050"],"award-info":[{"award-number":["2009-0094050"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapsed or refractory acute myeloid leukemia (R\/R <jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>) in elderly (\u226560\u00a0yr old) patients were eligible. Induction chemotherapy consisted fludarabine and cytarabine (<jats:styled-content style=\"fixed-case\">ARAC<\/jats:styled-content>) as a 24\u2010hr <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> without idarubicin (C\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content>), which was compared with the results of C\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content> with idarubicin (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content>2) in younger patients\u2019 trial. A total of 33 and 68 patients were enrolled in C\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content>2, respectively. <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> CR<\/jats:styled-content>p, and <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>i were achieved in 10 (30.3%), 3 (9.1%), and 2 (6.1%), respectively. When comparing outcomes between C\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content>2, there were no difference in terms of <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> rate (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.572) and objective response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>;<jats:italic> P<\/jats:italic>\u00a0=\u00a00.899). Favorable predictors on <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> in C\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content> were <jats:styled-content style=\"fixed-case\">PB WBC<\/jats:styled-content>\u00a0\u2264\u00a020K\/<jats:styled-content style=\"fixed-case\">uL<\/jats:styled-content> at salvage (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.024) and early evaluation peripheral <jats:styled-content style=\"fixed-case\">BLAST<\/jats:styled-content>\u00a0=\u00a00% (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.013) on multivariate analysis. The overall survival of patients who achieve <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>p\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>i showed significantly prolonged survival compared with patients who did not in C\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and was a favorable predictor of longer survival by multivariate analysis (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.009). Median overall survival was 3.19 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 2.05\u20134.33) months and similar with that of <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content>2 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.841). Attenuated salvage regimen C\u2010<jats:styled-content style=\"fixed-case\">FLGA<\/jats:styled-content> in elderly patients was as effective as more intensive younger patients\u2019 regimen <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">FLAG<\/jats:styled-content>2 in terms of response and survival although elderly patients had more unfavorable clinical characteristics.<\/jats:p>","DOI":"10.1111\/ejh.12568","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T15:03:04Z","timestamp":1429282984000},"page":"188-197","source":"Crossref","is-referenced-by-count":11,"title":["A prospective, multicenter phase <scp>II<\/scp> study of continuous infusion of <scp>FLAG<\/scp> for patients older than 60\u00a0yr with resistant acute myeloid leukemia: a comparison with intensive younger patients\u2019 trial"],"prefix":"10.1111","volume":"96","author":[{"given":"Hawk","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Hematology and Cellular Therapy Ulsan University Hospital University of Ulsan College of Medicine Ulsan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je\u2010Hwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology Asan Medical Center University of Ulsan College of Medicine Ulsan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young\u2010Don","family":"Joo","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Haeundae Paik Hospital Inje University College of Medicine Busan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hwa","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Daegu Catholic University Medical Center Catholic University of Daegu School of Medicine Daegu Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung\u2010Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology Asan Medical Center University of Ulsan College of Medicine Ulsan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae\u2010Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematology Asan Medical Center University of Ulsan College of Medicine Ulsan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won\u2010Sik","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Busan Paik Hospital Inje University College of Medicine Busan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hun\u2010Mo","family":"Ryoo","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Daegu Catholic University Medical Center Catholic University of Daegu School of Medicine Daegu Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae\u2010Cheol","family":"Jo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Cellular Therapy Ulsan University Hospital University of Ulsan College of Medicine Ulsan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunsuk","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Cellular Therapy Ulsan University Hospital University of Ulsan College of Medicine Ulsan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoo\u2010Hyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology Asan Medical Center University of Ulsan College of Medicine Ulsan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"CoOperative Study Group A for Hematology (COSAH)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522110-00004"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23337"},{"key":"e_1_2_8_4_1","first-page":"45","article-title":"Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I\/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group","volume":"4","author":"Avramis VI","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1997.15.8.2780","article-title":"Phase I\/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group","volume":"15","author":"Dinndorf PA","year":"1997","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199707000-00007"},{"key":"e_1_2_8_7_1","first-page":"1335","article-title":"Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia","volume":"100","author":"Ferrara F","year":"2002","journal-title":"Blood"},{"issue":"15","key":"e_1_2_8_8_1","first-page":"84","article-title":"Fludarabine and cytarabine as continuous sequential infusion plus liposomal daunorubicin (Daunoxome) as salvage therapy for refractory or relapsed patients with acute myeloid leukemia","volume":"88","author":"Camera A","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00135-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.06.013"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21351"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/943823"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.V96.5.1670","article-title":"How I treat older patients with AML","volume":"96","author":"Estey EH","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb03256.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1732-2"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70037-8"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.9743"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1165-z"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.222"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.08.009"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357093"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12568","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:18:46Z","timestamp":1696353526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,6]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/ejh.12568"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12568","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2015,5,6]]}}}